{
    "nct_id": "NCT04817007",
    "official_title": "A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis",
    "inclusion_criteria": "* Diagnosis of primary myelofibrosis (PMF), post-essential thrombocythemia (ET) or post-polycythemia vera (PV) myelofibrosis\n* Treatment-related toxicities from prior therapy resolved to Grade 1 or pre-treatment baseline or determined to be irreversible prior to study treatment\n* Must agree to follow specific methods of contraception, if applicable\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Women who are pregnant or breastfeeding at screening\n* Any significant acute or uncontrolled chronic medical illness\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}